We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Is Exact Sciences (EXAS) Stock Outpacing Its Medical Peers This Year?
Read MoreHide Full Article
Investors interested in Medical stocks should always be looking to find the best-performing companies in the group. Is Exact Sciences (EXAS - Free Report) one of those stocks right now? By taking a look at the stock's year-to-date performance in comparison to its Medical peers, we might be able to answer that question.
Exact Sciences is a member of our Medical group, which includes 951 different companies and currently sits at #4 in the Zacks Sector Rank. The Zacks Sector Rank considers 16 different sector groups. The average Zacks Rank of the individual stocks within the groups is measured, and the sectors are listed from best to worst.
The Zacks Rank is a proven system that emphasizes earnings estimates and estimate revisions, highlighting a variety of stocks that are displaying the right characteristics to beat the market over the next one to three months. Exact Sciences is currently sporting a Zacks Rank of #1 (Strong Buy).
Within the past quarter, the Zacks Consensus Estimate for EXAS' full-year earnings has moved 47.8% higher. This is a sign of improving analyst sentiment and a positive earnings outlook trend.
Based on the most recent data, EXAS has returned 17.8% so far this year. At the same time, Medical stocks have gained an average of 1.4%. As we can see, Exact Sciences is performing better than its sector in the calendar year.
Another Medical stock, which has outperformed the sector so far this year, is Amylyx Pharmaceuticals, Inc. (AMLX - Free Report) . The stock has returned 225.7% year-to-date.
For Amylyx Pharmaceuticals, Inc., the consensus EPS estimate for the current year has increased 8.1% over the past three months. The stock currently has a Zacks Rank #2 (Buy).
Breaking things down more, Exact Sciences is a member of the Medical - Biomedical and Genetics industry, which includes 469 individual companies and currently sits at #87 in the Zacks Industry Rank. Stocks in this group have gained about 11.7% so far this year, so EXAS is performing better this group in terms of year-to-date returns.
Amylyx Pharmaceuticals, Inc., however, belongs to the Medical - Drugs industry. Currently, this 144-stock industry is ranked #91. The industry has moved +2.9% so far this year.
Investors interested in the Medical sector may want to keep a close eye on Exact Sciences and Amylyx Pharmaceuticals, Inc. as they attempt to continue their solid performance.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Is Exact Sciences (EXAS) Stock Outpacing Its Medical Peers This Year?
Investors interested in Medical stocks should always be looking to find the best-performing companies in the group. Is Exact Sciences (EXAS - Free Report) one of those stocks right now? By taking a look at the stock's year-to-date performance in comparison to its Medical peers, we might be able to answer that question.
Exact Sciences is a member of our Medical group, which includes 951 different companies and currently sits at #4 in the Zacks Sector Rank. The Zacks Sector Rank considers 16 different sector groups. The average Zacks Rank of the individual stocks within the groups is measured, and the sectors are listed from best to worst.
The Zacks Rank is a proven system that emphasizes earnings estimates and estimate revisions, highlighting a variety of stocks that are displaying the right characteristics to beat the market over the next one to three months. Exact Sciences is currently sporting a Zacks Rank of #1 (Strong Buy).
Within the past quarter, the Zacks Consensus Estimate for EXAS' full-year earnings has moved 47.8% higher. This is a sign of improving analyst sentiment and a positive earnings outlook trend.
Based on the most recent data, EXAS has returned 17.8% so far this year. At the same time, Medical stocks have gained an average of 1.4%. As we can see, Exact Sciences is performing better than its sector in the calendar year.
Another Medical stock, which has outperformed the sector so far this year, is Amylyx Pharmaceuticals, Inc. (AMLX - Free Report) . The stock has returned 225.7% year-to-date.
For Amylyx Pharmaceuticals, Inc., the consensus EPS estimate for the current year has increased 8.1% over the past three months. The stock currently has a Zacks Rank #2 (Buy).
Breaking things down more, Exact Sciences is a member of the Medical - Biomedical and Genetics industry, which includes 469 individual companies and currently sits at #87 in the Zacks Industry Rank. Stocks in this group have gained about 11.7% so far this year, so EXAS is performing better this group in terms of year-to-date returns.
Amylyx Pharmaceuticals, Inc., however, belongs to the Medical - Drugs industry. Currently, this 144-stock industry is ranked #91. The industry has moved +2.9% so far this year.
Investors interested in the Medical sector may want to keep a close eye on Exact Sciences and Amylyx Pharmaceuticals, Inc. as they attempt to continue their solid performance.